Skip to main content

Table 12 In vitro cytotoxic activity [IC50 (μM)a] of compounds (19a-j) [54]

From: Therapeutic potential of oxadiazole or furadiazole containing compounds

Compound

Lung cancerA549c

Breast cancer

MCF-7b

MDA MB-231d

19a

9.78 ± 0.27

34.55 ± 2.34

–

19b

0.45 ± 0.03

1.76 ± 0.34

2.11 ± 0.21

19c

3.67 ± 0.18

2.89 ± 0.67

12.76 ± 0.81

19d

4.56 ± 0.19

2.33 ± 0.56

7.34 ± 0.26

19e

13.78 ± 1.78

12.4 ± 0.79

19.5 ± 2.11

19f

34.9 ± 2.30

15.3 ± 1.72

–

19g

1.03 ± 0.17

1.23 ± 0.30

1.89 ± 0.35

19h

2.45 ± 0.23

0.34 ± 0.025

1.11 ± 0.18

19i

1.89 ± 0.38

1.90 ± 0.41

3.78 ± 0.29

19j

87.5 ± 4.67

6.30 ± 0.35

22.5 ± 1.28

Doxorubicin

2.10 ± 0.14

3.12 ± 0.17

3.41 ± 0.23

  1. (–) not active, aEach data represents as mean ± S.D values. From three different experiments performed in triplicates. MCF-7: Human breast cancer cell line. cA549: Human lung cancer cell line. MDA MB-231d: Human breast cancer cell line
Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us